Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14. [PubMed: 16702586]

Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271–8. [PubMed: 22351712]

Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5 suppl 1):S30–S4. [PubMed: 12407574]

Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterol. 2010 Feb;138(2):513–21. [PubMed: 19861128]

National Center for HIV/AIDS VH, STD & TB Prevention. Disease Burden from Viral Hepatitis A, B, and C in the United States. Centers for Disease Control and Prevention; 2011. [Accessed on 10/27/11]. www​.cdc.gov/hepatitis/hcv/StatisticsHCV​.htm.

Swain M, Lai MY, Shiffman ML, et al. Durability of sustained virological response (SVR) after treatment with peginterferon alfa-2A (40KD) (PEGASYS) alone or in combination with ribavirin (COPEGUS): results of an ongoing long-term follow-up study. Hepatology (Baltimore, Md.). 2004;40(4 Suppl 1):400A–1A.

Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterol. 2010 Nov;139(5):1593–601. 2010. [PubMed: 20637202]

Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–16. [PubMed: 21397729]

Morgan TR, Ghany MG, Kim H-Y, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep;52(3):833–44. [PMC free article: PMC2932862] [PubMed: 20564351]

Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systematic review. Hepatology. 2002 Nov;36(5 Suppl 1):S135–44. [PubMed: 12407587]

Kjaegard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ. 2001;323:1151–5. [PMC free article: PMC59848] [PubMed: 11711405]

Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778–89. [PubMed: 8855176]

Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a systematic review. Hepatology. 2000;36:S135–44. [PubMed: 11134916]

Anonymous. National Institutes of Health consensus development conference statement: Management of hepatitis c: 2002--June 10–12, 2002. Hepatology. 2002;36(5 (Suppl 1)):S3–S20. [PubMed: 12407572]

Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74. [PMC free article: PMC7477893] [PubMed: 19330875]

Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;2004:1147–71. [PubMed: 15057920]

Foster GR. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther. 2004 Oct 15;20(8):825–30. [PubMed: 15479353]

Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology. 2010;51(4):1176–84. [PubMed: 20187106]

Chou RCS, Chan BKS. Drug Class Review on Pegylated Interferons for Chronic Hepatitis C Infection. Portland, OR: Oregon Health & Science University; 2007.

Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterol. 2010 Jan;138(1):116–22. [PubMed: 19852964]

Escudero A, Rodriguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008 Jun;23(6):861–6. [PubMed: 18422960]

McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580–93. [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1027] [PubMed: 19625712]

Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterol. 2010 Jan;138(1):108–15. [PubMed: 19766645]

Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentratiosn in participants of a general population survey in the United States. Gastroenterol. 2006;131:478–84. [PubMed: 16890602]

Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. [PubMed: 19684573]

Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet. 2009;41(10):1100–4. [PubMed: 19749758]

Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975–82. [PubMed: 12324553]

FDA. Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV). 2011. www​.fda.gov/ForConsumers​/ByAudience/ForPatientAdvocates​/ucm255413.htm.

FDA. Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). 2011. www​.fda.gov/ForConsumers​/ByAudience/ForPatientAdvocates​/ucm256328.htm.

Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28;376(9742):705–16. [Erratum appears in Lancet. 2010 Oct 9;376(9748):1224 Note: SPRINT-1 investigators [added]; multiple investigator names added] [PubMed: 20692693]

McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009 Apr 30;360(18):1827–38. [Erratum appears in N Engl J Med. 2009 Oct 8;361(15):1516] [PubMed: 19403902]

Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195–206. [PMC free article: PMC3766849] [PubMed: 21449783]

PEGASYS [package insert]. Nutley, NJ: Hoffmann-La Roche Inc; 2002.

PEG-Intron [package insert]. Kenilworth, NJ: Schering Corporation; 2005.

Chou R, Cottrell E, Wasson N, et al. Screening for Hepatitis C Virus Infection in Adults: Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality; 2012. (Prepared by Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I) Forthcoming. [PubMed: 23304739]

Pembrey L, Newell M-L, Tovo P-A, et al. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol. 2005;43(3):515–25. [PubMed: 16144064]

Ghany M, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology. 2011 Oct;54(4):1433–44. [PMC free article: PMC3229841] [PubMed: 21898493]

Lindsay KL. Introduction to therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S114–20. [PubMed: 12407584]

Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol. 1999;31(Suppl 1):237–43. [PubMed: 10622595]

Hung CH, Lee CM, Lu SN, et al. Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol. 2002;17(12):1307–11. [PubMed: 12423276]

Zeuzem S, Feinman S, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666–72. [PubMed: 11106715]

Basso M, Giannini EG, Torre F, et al. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA–negative patients are associated with virological relapse. Hepatology. 2009;49(5):1442–8. [PubMed: 19350657]

Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–84. [PMC free article: PMC1756728] [PubMed: 9764259]

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl):21–35. [PubMed: 11306229]

AHRQ. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2011. [PubMed: 21959053]

Shibuya K, Yano E. Regression analysis of trends in mortality from hepatocellular carcinoma in Japan, 1972–2001. Int J Epidemiol. 2005;34(2):397–402. [PubMed: 15561746]

Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4(1):38. [PMC free article: PMC545647] [PubMed: 15615589]

Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol. 2011 Nov;64(11):1187–97. [PubMed: 21477993]

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. [PubMed: 12111919]

Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. British Medical Journal. 2011 Jul;343(1):d4002. 2011. [PubMed: 21784880]

Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16. [PubMed: 21696307]

Bronowicki J-P, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterol. 2006 Oct;131(4):1040–8. [PubMed: 17030174]

Kamal SM, Ahmed A, Mahmoud S, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int. 2011;31(3):401–11. [PubMed: 21281434]

Khan A, Awan A, Shahbuddin S, et al. Abstract # S1231: Peginterferon alfa 2a/ribavirin versus peginterferon alfa 2b/ribavirin combination therapy in chronic hepatitis C genotype 3. Gastroenterol. 2007;132(4):A200.

Mach TH, Ciesla A, Warunek W, et al. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej. 2011;121(12):434–40. [PubMed: 22157768]

Magni CNF, Argenteri B, Giorgi R, Mainini A, Pastecchia C, Ricci E, Schiavini M, Terzi R, Vivirito MC, Resta M. Abstract #883: Antiviral activity and tolerability between pegylated interferon alpha 2a and alpha 2b in naive patients with chronic hepatitis C: Results of a prospective monocentric randomized trial. Hepatology. 2009;50(S4):720A.

Miyase S, Haraoka K, Ouchida Y, et al. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol. 2012:1–8. [PubMed: 22382633]

Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol. 2006 Jun;17(2):94–8. [PubMed: 16830289]

Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterol. 2011 Feb;140(2):459–68.e1. quiz e14. [PubMed: 21034744]

McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2008;15(7):475–81. [PubMed: 18363672]

Andriulli A, Cursaro C, Cozzolongo R, et al. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. J Viral Hepat. 2009 Jan;16(1):28–35. [PubMed: 18761603]

Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008 Jan;47(1):35–42. [PubMed: 17975791]

Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346–55. [PubMed: 14996676]

Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008 Jun;47(6):1837–45. [PubMed: 18454508]

Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609–17. [PubMed: 15972867]

Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol. 2011;55(3):554–63. [PubMed: 21237227]

Mecenate F, Pellicelli AM, Barbaro G, et al. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterol. 2010;10:21. [PMC free article: PMC2837223] [PubMed: 20170514]

Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007 Jul 12;357(2):124–34. [PubMed: 17625124]

von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterol. 2005 Aug;129(2):522–7. [PubMed: 16083709]

Yu M-L, Dai C-Y, Huang J-F, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007 Apr;56(4):553–9. [PMC free article: PMC1856839] [PubMed: 16956917]

Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterol. 2004 Dec;127(6):1724–32. [PubMed: 15578510]

Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology. 2010 Nov;52(5):1573–80. [PubMed: 21038410]

Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat. 2006 Dec;13(12):811–20. [PubMed: 17109680]

Kawaoka T, Kawakami Y, Tsuji K, et al. Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial. J Gastroenterol Hepatol. 2009 Mar;24(3):366–71. [PubMed: 19032459]

Krawitt EL, Gordon SR, Grace ND, et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol. 2006 Jun;101(6):1268–73. [PubMed: 16771948]

Meyer-Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat. 2006 Jul;13(7):457–65. [PubMed: 16792539]

Sood A, Midha V, Hissar S, et al. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol. 2008 Feb;23(2):203–7. [PubMed: 17645472]

Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65. [PubMed: 11583749]

Mimidis K, Papadopoulos VP, Elefsiniotis I, et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis. 2006 Sep;15(3):213–9. [PubMed: 17013444]

Ferenci P, Brunner H, Laferl H, et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008 Jun;47(6):1816–23. [PubMed: 18454510]

Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006 Nov;13(11):762–9. [PubMed: 17052276]

Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007 Oct;46(4):971–81. [PubMed: 17894303]

Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterol. 2010 Feb;138(2):503–12. [Reprint in Korean J Hepatol. 2010 Jun;16(2):201–5; PMID: 20606507] [PubMed: 19909752]

Merck & Co I, editor. Bocepriver [package insert]. Whitehouse Station, NJ: Merck & Co, Inc.; 2011.

Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009 Apr 30;360(18):1839–50. [PubMed: 19403903]

Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78–84. [PubMed: 21827730]

Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–24. [PMC free article: PMC3809077] [PubMed: 21916639]

Lok A. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):273–5. [PubMed: 22256805]

Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50(1):16–23. [PubMed: 17164553]

Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007 Mar;45(3):579–87. [PubMed: 17326216]

Cardoso A-C, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010 May;52(5):652–7. [PubMed: 20346533]

Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004 Apr;99(4):636–44. [PubMed: 15089895]

El Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007;13(42):5648–53. [PMC free article: PMC4172746] [PubMed: 17948941]

Fernández-Rodríguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response. Am J Gastroenterol. 2010 [PubMed: 20700116]

Hasegawa E, Kobayashi M, Kawamura Y, et al. Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res. 2007;37(10):793–800. [PubMed: 17593231]

Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13(6):409–14. [PubMed: 16842444]

Imazeki F, Yokosuka O, Fukai K, et al. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003 Aug;38(2):493–502. [PubMed: 12883494]

Innes HA, Hutchinson SJ, Allen S, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54(5):1547–58. [PubMed: 22045672]

Izumi N, Yasuhiro A, Kurosaki M, et al. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy? Intervirology. 2005;48(1):59–63. [PubMed: 15785091]

Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 2004 Mar;11(2):148–56. [PubMed: 14996350]

Maruoka D, Imazeki F, Arai M, et al. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27(2):291–9. [PubMed: 21793911]

Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005 Jan 18;142(2):105–14. [PubMed: 15657158]

Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–84. [PubMed: 18025443]

Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterol. 2002 Aug;123(2):483–91. [PubMed: 12145802]

Yu M-L, Lin S-M, Chuang W-L, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antiver Ther. 2006;11(8):985–94. [PubMed: 17302368]

Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399–403. [PubMed: 18794559]

Arora S, O’Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006 Feb;21(2):406–12. [PubMed: 16509866]

Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002 Mar;35(3):704–8. [PubMed: 11870387]

Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther. 2006;23(6):777–85. [PubMed: 16556180]

Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29(1):264–70. [PubMed: 9862876]

Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004 Apr;40(4):675–81. [PubMed: 15030985]

McHutchison J, Manns M, Harvey J, et al. Adherence to therapy enhanges sustained response in chronic hepatitis C patients receiving PEG-Interferon alfa-2b plus Ribavirin [abstract] J Hepatol. 2001;34(1):2–3.

Neary MP, Cort S, Bayliss MS, et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19(Suppl 1):77–85. [PubMed: 10349695]

Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics. 2003;21(5):341–9. [Erratum appears in Pharmacoeconomics. 2003;21(17):1290] [PubMed: 12627987]

Ware JE, Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999;30(2):550–5. [PubMed: 10421667]

Myles PS, Davis BB. “Low SVR syndrome” or SIRS after cardiac operations? Ann Thorac Surg. 1998;65(1):298. [PubMed: 9456150]

McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339(21):1485–92. [PubMed: 9819446]

Tong MJ, Blatt LM, McHutchison JG, et al. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology. 1997;26(6):1640–5. [PubMed: 9398010]

Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004 Jun;40(6):993–9. [see comment][erratum appears in J Hepatol. 2005 Mar;42(3):434] [PubMed: 15158341]

Shepherd J, Brodin HFT, Cave CB, et al. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care. 2005;21(1):47–54. [PubMed: 15736514]

Siebert U, Sroczynski G, et al. German Hepatitis CMGEHMOG. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care. 2005;21(1):55–65. [PubMed: 15736515]

Zaman A, Fennerty MB, Keeffe EB. Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. Aliment Pharmacol Ther. 2003 Oct 1;18(7):661–70. [PubMed: 14510739]

Background Material for Boceprevir Advisory Committee. FDA. 2011. www​.fda.gov/downloads​/AdvisoryCommittees​/CommitteesMeetingMaterials​/drugs/AntiviralDrugsAdvisoryCommittee/ucm252341.pdf.

Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011 Aug;56(8):2221–6. [PubMed: 21643737]

Singal AK, Anand BS. Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials. J Clin Gastroenterol. 2010;44(8):583–7. [PubMed: 20375729]

Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52(7):889–900. [PubMed: 21427396]

Garg V, van Heeswijk R, Eun Lee J, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011;54(1):20–7. [PubMed: 21618566]

El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. [PubMed: 21992124]

Morrison A, Moulton K, Clark M, et al. English-Language Restriction When Conducting Systematic Review-based Metaanalyses: Systematic Review of Published Studies. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.

Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ. 2004;170(4):477–80. [PMC free article: PMC332713] [PubMed: 14970094]

Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31;326(7400):1167–70. [PMC free article: PMC156458] [PubMed: 12775614]